Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446986 | 0.90 | NPC1 (0.42) | NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL25446988 | 0.89 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL25478482 | 0.85 | NPC1 (0.42) | NPC1RAB9ATSHR | |
| SCHEMBL23135532 | 0.76 | MAPK1 (0.41) | — | |
| SCHEMBL20697033 | 0.71 | TYK2 (0.42) | TYK2 | |
| SCHEMBL20688004 | 0.70 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1KAT2BBAZ2BCNR2 | |
| SCHEMBL13753394 | 0.70 | RAB9A (0.55) | NPC1RAB9APKMSMN1; SMN2TSHR | |
| SCHEMBL20689622 | 0.68 | TYK2 (0.45) | PKMSMN1; SMN2TYK2 | |
| SCHEMBL1812388 | 0.66 | KDM4E (0.43) | NPC1RAB9AHRH3ALDH1A1 | |
| SCHEMBL21246029 | 0.66 | CNR2 (0.39) | SMN1; SMN2CNR2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | HTR4 4055/4885KCNK3 3319/4885NPC1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.